The Inherited Cancer Registry (ICARE) Initiative: An Academic-Community Partnership for Patients and Providers

References

• Watson M, Kash KM, Homewood J, et al. Does genetic counseling have any impact on management of breast cancer risk? Genet Test. 2005; 9: 167–174.
   PubMedGoogle Scholar
• Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007; 4: 578–590.
   PubMedGoogle Scholar
• Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol. 2005; 23: 1656–1663.
   PubMed Web of Science ®Google Scholar
• Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006; 98: 1694–1706.
   PubMed Web of Science ®Google Scholar
• Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104: 2807–2816.
   PubMed Web of Science ®Google Scholar
• John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 U.S. racial/ethnic groups. JAMA. 2007; 298: 2869–2876.
   PubMed Web of Science ®Google Scholar
• Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006; 66: 8297–8308.
   PubMed Web of Science ®Google Scholar
• Pearlman R, Frankel WL, Swanson B, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017; 3: 464–471.
   PubMed Web of Science ®Google Scholar
• Dillon JL, Gonzalez JL, DeMars L, Bloch KJ, Tafe LJ. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome. Hum Pathol. 2017; 70: 121–128.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304: 967–975.
   PubMed Web of Science ®Google Scholar
• Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014; 32: 1547–1553.
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol. 2012; 9: 520–528.
   PubMed Web of Science ®Google Scholar
• Tinoco G, Warsch S, Gluck S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013; 4: 117–132.
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017; 377: 523–533.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372: 2509–2520.
   PubMed Web of Science ®Google Scholar
• Westdorp H, Kolders S, Hoogerbrugge N, de Vries IJM, Jongmans MCJ, Schreibelt G. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Lett. 2017; 403: 159–164.
   Web of Science ®Google Scholar
• Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract. 2016; 3: 1–8. Available online at: https://gynoncrp.biomedcentral.com/articles/10.1186/s40661-016-0024-7. Last accessed October 10, 2018.
   Google Scholar
• Cragun D, Pal T. Identification, evaluation, and treatment of patients with hereditary cancer risk within the United States. ISRN Oncol. 2013; 2013: 260847.
   PubMedGoogle Scholar
• Evans DG, Barwell J, Eccles DM, et al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014; 16: 1–6. Available online at: https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0442-6. Last accessed October 10, 2018.
   Web of Science ®Google Scholar
• Bradbury AR, Patrick-Miller L, Long J, et al. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med. 2015; 17: 485–492.
   PubMed Web of Science ®Google Scholar
• Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a U.S. laboratory. Clin Genet. 2014; 86: 510–520.
   PubMed Web of Science ®Google Scholar
• Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs. guideline-based germline testing. JAMA. 2017; 318: 825–835.
   PubMed Web of Science ®Google Scholar
• Mai PL, Vadaparampil ST, Breen N, McNeel TS, Wideroff L, Graubard BI. Awareness of cancer susceptibility genetic testing: the 2000, 2005, and 2010 National Health Interview Surveys. Am J Prev Med. 2014; 46: 440–448.
   PubMed Web of Science ®Google Scholar
• Pal T, Cragun D, Lewis C, et al. A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers. 2013; 17: 367–375.
   PubMed Web of Science ®Google Scholar
• Cragun D, Scherr C, Camperlengo L, Vadaparampil ST, Pal T. Evolution of hereditary breast cancer genetic services: are changes reflected in the knowledge and clinical practices of Florida providers? Genet Test Mol Biomarkers. 2016; 20: 569–578.
   PubMed Web of Science ®Google Scholar
• Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN. Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of U.S. physicians. J Med Genet. 2005; 42: 749–755.
   PubMed Web of Science ®Google Scholar
• Blazer KR, Nehoray B, Solomon I, et al. Next-generation testing for cancer risk: perceptions, experiences, and needs among early adopters in community healthcare settings. Genet Test Mol Biomarkers. 2015; 19: 657–665.
   PubMed Web of Science ®Google Scholar
• Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017; 35: 2232–2239.
   PubMed Web of Science ®Google Scholar
• Caswell-Jin JL, Gupta T, Hall E, et al. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet Med. 2017; 20: 234–239.
   Web of Science ®Google Scholar
• Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016; 13: 581–588.
   PubMed Web of Science ®Google Scholar
• Manolio TA, Murray MF. The growing role of professional societies in educating clinicians in genomics. Genet Med. 2014; 16: 571–572.
   Web of Science ®Google Scholar
• Bookman T. More people seek genetic testing, but there aren't enough counselors. 2016. Available online at: https://www.npr.org/sections/health-shots/2016/04/18/473066953/more-people-seek-genetic-testing-but-there-arent-enough-counselors. Last accessed October 10, 2018.
   Google Scholar
• Occupational employment statistics: occupational employment and wages, May 2015: 29-9092 genetic counselors. Available online at: https://www.bls.gov/oes/2015/may/oes299092.htm. Last accessed March 30, 2016.
   Google Scholar
• Acheson LS, Stange KC, Zyzanski S. Clinical genetics issues encountered by family physicians. Genet Med. 2005; 7: 501–508.
   Web of Science ®Google Scholar
• Vig HS, Armstrong J, Egleston BL, et al. Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers. 2009; 13: 735–741.
   PubMed Web of Science ®Google Scholar
• Radford C, Prince A, Lewis K, Pal T. Factors which impact the delivery of genetic risk assessment services focused on inherited cancer genomics: expanding the role and reach of certified genetics professionals. Genet Couns. 2014; 23: 522–530.
   Web of Science ®Google Scholar
• Cragun D, Bonner D, Kim J, et al. Factors associated with genetic counseling and BRCA testing in a population-based sample of young black women with breast cancer. Breast Cancer Res Treat. 2015; 151: 169–176.
   PubMed Web of Science ®Google Scholar
• Cragun, D, Sherr C, Camperlengo L, Vadaparampil S, Pal T. Evolution of hereditary breast cancer genetic services: are changes reflected in the knowledge and clinical practices of Fl providers. Genet Test Mol. 2016; 20(10): 569–578.
   PubMed Web of Science ®Google Scholar
• Cragun D, Camperlengo L, Robinson E, et al. Differences in BRCA counseling and testing practices based on ordering provider type. Genet Med. 2014; 17: 51–57.
   Web of Science ®Google Scholar
• Whitworth P, Beitsch P, Arnell C, et al. Impact of payer constraints on access to genetic testing. J Oncol Pract. 2017; 13: e47–e56.
   Web of Science ®Google Scholar
• Pal T, Lee JH, Besharat A, et al. Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clin Genet. 2013; 85: 49–53.
   Web of Science ®Google Scholar
• ACOG committee opinion no. 527: Personalized genomic testing for disease risk. Obstet Gynecol. 2012; 119: 1318–1319.
   Google Scholar
• Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015; 33: 3660–3667.
   PubMed Web of Science ®Google Scholar
• Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013; 160: 271–281.
   Web of Science ®Google Scholar
• Genetic/familial high-risk assessment: breast and ovarian. In: NCCN Practice Guidelines. 2017. Available online at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Last accessed October 10, 2018.
   Google Scholar
• NAPBC/CoC. 2014 Breast Center Standards Manual Through the National Accrreditation Program for Breast Centers (NAPBC). 2015. Available online at: https://www.facs.org/~/media/files/quality%20programs/napbc/2014%20napbc%20standards%20manual.ashx. Last accessed October 10, 2018.
   Google Scholar
• NAPBC/CoC. Cancer Program Standards: Ensuring Patient-Centered Care. Chicago, IL: 2016. Available online at: https://www.facs.org/quality-programs/cancer/coc/standards. Last accessed October 10, 2018.
   Google Scholar
• Cragun D, Besharat AD, Lewis C, Vadaparampil ST, Pal T. Educational needs and preferred methods of learning among Florida practitioners who order genetic testing for hereditary breast and ovarian cancer. J Cancer Educ. 2013; 28: 690–697.
   Web of Science ®Google Scholar
• Vadaparampil ST, Scherr CL, Cragun D, Malo TL, Pal T. Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida. Clin Genet. 2014; 87: 473–477.
   Web of Science ®Google Scholar
• Kotsopoulos J, Huzarski T, Gronwald J, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2017; 109: 1–7.
   Google Scholar
• Kotsopoulos J, Lubinski J, Gronwald J, et al. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2015; 137: 1136–1146.
   Web of Science ®Google Scholar
• Gronwald J, Glass K, Rosen B, et al. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril. 2016; 105: 781–785.
   Web of Science ®Google Scholar
• Cragun D, Kinney AY, Pal T. Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing. 2017; 17: 57–70.
   Google Scholar
• Pal T, Brzosowicz J, Valladares A, Wiesner GL, Laronga C. Identification and management of TP53 gene carriers detected through multigene panel testing. South Med J. 2017; 110: 643–648.
   Web of Science ®Google Scholar